The Life Sciences team advised Biotheus Inc. on its exclusive global license and collaboration agreement with BioNTech. BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China. PM8002 is currently being tested in Phase 2 studies in China to evaluate the efficacy and safety of the candidate as a monotherapy or in combination with chemotherapy in patients with advanced solid tumors.
Under the terms of the agreement, Biotheus will receive an upfront payment of $55 million, and is eligible to receive additional development, regulatory and sales milestone payments potentially totaling over $1 billion as well as tiered royalties on potential future product sales.
Biotheus Inc. is a clinical-stage biotech company dedicated to the discovery, development, and delivery of novel antibodies and cell therapies to address the unmet medical needs of patients with oncology and inflammatory diseases worldwide.
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
The Goodwin team was led by Wenseng “Wendy” Pan and consisted of Kevin Guan, Longfei Fang, Susan Lee, Lily Xu, Paul Jin and Michael Casaburi.
For more details, read the press release and articles in Endpoints News and Fierce Biotech.